WARREN, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that Mittul Mehta, Chief Information Officer of Tevogen and Head of Tevogen.AI, will participate as a panelist in the Startup Forum at the Databricks DATA + AI World Tour on October 8, 2025. The Startup Forum will feature insights from venture capital leaders and early-stage innovators on how they are scaling their companies with Databricks. Mehta will join industry peers incl ...

Risk adjusted Net Present Value (rNPV) for TVGN 116 is estimated to exceed ~$325 million in the US alone. WARREN, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today shared asset value and potential forecast for the Company’s pipeline product, TVGN 116, for liver cancer prevention with high-risk chronic Hepatitis B infections. The TVGN 116 cumulative 5-year top-line revenue forecast is estimated to be ~$6.5 billion. The forecast reflects the Comp ...

WARREN, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today shared the risk-adjusted net present value (rNPV) estimate of $9 billion to $11 billion for TVGN-489, an allogeneic precision T cell therapy and the first clinical-stage product from its proprietary ExacTcell™ platform. TVGN-489 is being developed for the treatment of SARS-CoV-2 infection in high-risk vulnerable patients and for Long-COVID in patients with evidence of a persistent viral ...

The risk adjusted Net Present Value (rNPV) for TVGN 930 is estimated to exceed ~$250 million in the US alone.Covering five rare disease eligible indications, the accessible market in the US could be as high as 40,000 patients.Focused on improved prognosis for patients with hematologic malignancies. WARREN, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today shared asset value and potential forecast for the Company’s pipeline product, TVGN 930, fo ...

Core Viewpoint - Tevogen Bio Holdings Inc. emphasizes the ongoing need for effective SARS-CoV-2 treatments, particularly for individuals with weakened immune systems, highlighting the potential of its investigational therapy TVGN 489 to enhance immunity and eliminate the virus [1][3] Group 1: Product Development and Clinical Trials - TVGN 489 is an allogeneic SARS-CoV-2-specific Cytotoxic CD8+ T lymphocyte immunotherapy developed using the ExacTcell platform, targeting the entire viral genome rather than just a single protein [1] - Positive clinical trial data indicates that in the treatment arm, viral elimination reached over 99% in all patients by day 14, with no disease progression or Long COVID observed [6] - The treatment was well-tolerated across all dose levels, and CTLs persisted in treated patients for up to six months, suggesting a durable immune response [6] Group 2: Market Context and Challenges - The emergence of the XFG variant of SARS-CoV-2 underscores the ongoing threat of COVID-19, particularly for vulnerable populations, necessitating continuous surveillance and treatment efforts [3] - The company acknowledges the challenges posed by mutation-prone viruses, indicating that targeting only the spike protein is insufficient for effective treatment [3] Group 3: Future Outlook - Tevogen's leadership expresses confidence in the potential of TVGN 489 to provide necessary immune support for high-risk patients, emphasizing the importance of innovative therapies in the face of evolving viral threats [3]

Core Insights - Tevogen Bio Holdings Inc. has significant internally developed assets that are not reflected on its balance sheet but represent substantial long-term value [1][3] - The company plans to provide detailed information and valuation of these assets in the near future [1] Asset Overview - Key assets include PredicTcell™, which utilizes AI algorithms to predict peptide–T cell receptor interactions, thereby accelerating development and expanding the pipeline [1] - AdapTcell™ employs AI models to decode HLA–T cell interactions, enhancing immune system insights and revealing new therapeutic paths [2] Intellectual Property and Technology - Tevogen holds three granted U.S. patents and has twelve pending U.S. patents, including two related to artificial intelligence [6] - The company has strategic collaborations with Microsoft and Databricks to support its AI technology [6] Drug Development and Clinical Pipeline - The ExacTcell™ platform focuses on highly purified, target-specific CD8+ cytotoxic T lymphocytes (CTL) [6] - The clinical pipeline includes therapeutics designed to treat cancers while allowing patients to continue oncology care, with potential expansion into non-oncology indications [6] Financial Position - Tevogen has access to a line of credit and is well-capitalized for current operations [6] - The company is establishing internal GMP manufacturing capabilities [6] Facilities - Tevogen operates a drug discovery lab in Philadelphia and has its headquarters in New Jersey [6]

Core Insights - Tevogen Bio Holdings Inc. has been recognized by Yale University for its commitment to health equity and the leadership of its Founder and CEO, Dr. Ryan Saadi [2] - The company operates with a lean, capital-efficient business model, fully owning its core intellectual property to minimize costs and complexity in developing CD8+ T cell therapies [3] - Dr. Saadi emphasized that affordability and accessibility are foundational to Tevogen's operations, achieving significant milestones with lower capital expenditure compared to industry norms [4] Business Model and Strategy - Tevogen's business model is designed to withstand market pressures through a capital-efficient structure, focusing on off-the-shelf, genetically unmodified therapies [3] - The company has avoided the typical billion-dollar burn rate seen in the industry, maintaining a lean cash run rate while preserving equity [4] - Tevogen aims to deliver innovative therapies that not only improve patient outcomes but also achieve commercial success at a lower cost [4] Recognition and Impact - The recognition from Yale highlights the impact of Tevogen's mission on making healthcare more affordable and accessible [2] - Dr. Saadi's vision is acknowledged as a significant contribution to the healthcare landscape, reinforcing the company's commitment to health equity [2][4]

Core Viewpoint - Tevogen Bio Holdings Inc. has reported a significant increase in institutional ownership of its common stock, indicating growing confidence from long-term investors in the company's scientific and operational progress [2][3]. Institutional Ownership Update - As of June 30, 2025, institutional ownership of Tevogen common stock rose by 24% compared to March 31, 2025, following a 60% increase in the first quarter [2]. - The number of institutional holders increased from 51 to 55, with 72% of these holders either increasing or maintaining their positions [2]. Key Contributors - Major contributors to the second quarter growth in institutional ownership were Morgan Stanley and BlackRock, which collectively increased their holdings by 80% [2]. Management Commentary - The Head of Investor Relations at Tevogen stated that the increase in institutional ownership is a positive sign, reflecting the company's scientific advancements and operational milestones, such as positive clinical data and progress towards internal GMP cell manufacturing capabilities [3].

Core Insights - Tevogen Bio Holdings Inc. has been recognized in BINJE's BEST Health Care 2025 for its commitment to health equity and innovation in sustainable biopharma [1][2] - The company's focus is on developing affordable and safe T cell therapies for acute viral infections and cancers, utilizing its proprietary ExacTcell™ platform [2] Company Overview - Tevogen Bio is dedicated to advancing health equity by ensuring access to life-saving medications through a sustainable biopharma model [2] - The company operates a lean, capital-efficient structure that avoids licensing overhead by fully owning its core intellectual property [2] - Tevogen's CD8+ T cell therapies are designed to reduce manufacturing complexity and costs, aligning with U.S. healthcare priorities [2] Technological Advancements - The launch of Tevogen.AI aims to accelerate therapeutic discovery and development through advanced algorithms and partnerships with Microsoft and Databricks [2] Recognition and Community - Tevogen expresses gratitude to BINJE and congratulates other honorees in the health care sector for their achievements [3]

Core Insights - Tevogen Bio Holdings Inc. has been recognized in BINJE's BEST Health Care 2025 for its commitment to health equity and innovation in sustainable biopharma [1][2] - The company's focus is on developing affordable T cell therapies for acute viral infections and cancers, utilizing its proprietary ExacTcell™ platform [2] Company Overview - Tevogen Bio is dedicated to advancing health equity by ensuring access to life-saving medications through a sustainable biopharma model [2] - The company operates a lean, capital-efficient structure that avoids licensing overhead by fully owning its core intellectual property [2] - Tevogen's CD8+ T cell therapies are designed to reduce manufacturing complexity and costs, aligning with U.S. healthcare priorities [2] Technological Advancements - The launch of Tevogen.AI aims to accelerate therapeutic discovery and development through advanced algorithms and partnerships with Microsoft and Databricks [2] Recognition and Community - Tevogen expresses gratitude to BINJE and congratulates other honorees in the health care sector for their achievements [3]